IPIX (Innovation Pharmaceuticals) Liabilities-to-Assets : 0.83 (As of Sep. 2023)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

What is Innovation Pharmaceuticals Liabilities-to-Assets?

Innovation Pharmaceuticals IPIX Liabilities-to-Assets is 0.83 as of Sep. 2023.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Innovation Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2023 was $5.51 Mil. Innovation Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $6.67 Mil. Therefore, Innovation Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 0.83.

Innovation Pharmaceuticals (OTCPK:IPIX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Innovation Pharmaceuticals Liabilities-to-Assets Related Terms

Innovation Pharmaceuticals Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Liabilities-to-Assets Chart

Innovation Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Liabilities-to-Assets

Get a 7-Day Free Trial

2.02

0.84

0.48

0.54

0.73

Innovation Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Liabilities-to-Assets	Get a 7-Day Free Trial															0.63	0.65	0.66	0.73	0.83

IPIX vs AXIM, RNAZ, APTX: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Innovation Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation Pharmaceuticals Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Liabilities-to-Assets falls into.

Save Embed

Innovation Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Innovation Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Liabilities-to-Assets (A: Jun. 2023 )	=	Total Liabilities	/	Total Assets
	=	5.478	/	7.517
	=	0.73

Innovation Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 is calculated as

Liabilities-to-Assets (Q: Sep. 2023 )	=	Total Liabilities	/	Total Assets
	=	5.505	/	6.667
	=	0.83

Frequently Asked Questions Learn more about Liabilities-to-Assets →

What does a Liabilities-to-Assets of 0.83 mean?

Innovation Pharmaceuticals (IPIX) has a Liabilities-to-Assets of 0.83 as of Sep. 2023. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Innovation Pharmaceuticals and its competitors.

Is Innovation Pharmaceuticals' Liabilities-to-Assets too high?

Innovation Pharmaceuticals' current Liabilities-to-Assets is 0.83.

How does Innovation Pharmaceuticals' Liabilities-to-Assets compare to AXIM and RNAZ?

Innovation Pharmaceuticals' Liabilities-to-Assets of 0.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Liabilities-to-Assets for a Biotechnology company?

A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Liabilities-to-Assets mean?

A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Liabilities-to-Assets is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Innovation Pharmaceuticals stock overvalued right now?

Innovation Pharmaceuticals (IPIX) has a current Liabilities-to-Assets of 0.83. The current Liabilities-to-Assets is 0.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Liabilities-to-Assets calculated?

Liabilities-to-Assets is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Liabilities-to-Assets is 0.83 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies AXIM RNAZ APTX CPMV VRAX KPRX NEXI QRON ENDV ENVB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880

Website http://www.ipharminc.com

Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.